RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25

Revolution Medicines’ pan-RAS inhibitor delivered a landmark Phase 3 survival readout at AACR25 that doubled survival, setting off what the oncology field is calling a RAS bonanza.

RevMed’s result cleared a benchmark that’s historically been hard to hit in cancer medicine. The RAS pathway has resisted targeted therapy for years. A doubled-survival signal from Phase 3 resets the commercial and scientific calculus for this drug class.

The oncology field is buzzing after the AACR25 readout. A pan-RAS drug doubling survival in Phase 3 sets a new benchmark, accelerating attention on the RAS pathway after years of resistance to targeted therapy.

For RevMed, the survival data accelerates every downstream conversation: partnership valuations, regulatory timelines, and investor positioning. A Phase 3 win at this level, in a notoriously hard-to-drug target class, puts the company in a strong position heading into an FDA filing.

Next milestone: a regulatory submission timeline, as AACR25 momentum pushes RevMed toward FDA.

— Sarah Chen